Hims & Hers Health Inc (NYSE: HIMS) started this week on a positive note after announcing its expansion into menopause-related treatments – a large and underserved market. However, the rally is fading rather quickly. On Friday, the telehealth stock tanked another 15% as Andrew Dudum, the company’s chief executive, confirmed he’s sold over $11 million











